Maxigen Biotech Inc. (1783.TW)

TWD 46.3

(-0.43%)

Market Cap (In TWD)

4.12 Billion

Revenue (In TWD)

622.11 Million

Net Income (In TWD)

165.82 Million

Avg. Volume

370.34 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
37.25-51.5
PE
-
EPS
-
Beta Value
0.885
ISIN
TW0001783009
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Ms. Ching-Ting Chen
Employee Count
-
Website
https://www.mbi.com.tw
Ipo Date
2012-10-03
Details
Maxigen Biotech Inc. engages in the development, manufacture, and marketing of biomedical and skincare products in Taiwan and internationally. The company offers Formagraft, a bone graft substitute; Formasetin, a bone void filler; and intra-articular injections under the ArtiAid, ArtiAid Plus, and ArtiBest names for use in orthopedic area. It also provides Foramic, a bone substitute granule; MaxiBone, a calcium phosphate ceramic; and GingivAid, a collagen dental grafts for use in orthopedic and dental areas. In addition, the company offers FormaAid, a collagen membrane; and E-TECH DENTISTAR II sterilizer and disinfectant for use in dental area, as well as HealiAid, a collagen wound dressing product for use in dental and wound dressing area. Further, it provides ophthalmic viscoelastic device under the ViscAid, PreviscAid, and BiVisc names; and Formaderm, a dermal filler injection for use in plastic surgery. Additionally, the company offers skincare products, including face, neck, body, limbs, and other masks; and make up remover, cleansing, exfoliating, toner, essence, men's care, sunscreen, body care, hand/foot care, and special care products. Maxigen Biotech Inc. was founded in 1998 and is based in Taoyuan City, Taiwan.